BioCentury
ARTICLE | Clinical News

FDA accepts Icon's NDA for ophthalmic product Dexycu

August 18, 2017 4:30 PM UTC

In June, Icon Bioscience Inc. (Newark, Calif.) said FDA accepted for review an NDA for Dexycu (IBI-10090) to reduce inflammation after cataract surgery. Its PDUFA date is Feb. 12, 2018. The company e...

BCIQ Company Profiles

Icon Bioscience Inc.